| Literature DB >> 35401206 |
Lianping Wei1, Wenhao Dong1, Zhen Han2, Chen Chen1, Qing Jin1, Jinling He1, Yongping Cai1.
Abstract
Globally, gastric cancer (GC) is one of the three most deadly cancers. Dendrobium officinale (D. officinale) is a traditional Chinese medicine (TCM), and its extract can significantly inhibit the proliferation of gastric cancer cells. However, there are no unified conclusions on its potential active components and possible mechanisms of action. This paper aims at exploring the potential active components, targets, and cell pathways of D. officinale extract in inhibiting the proliferation of gastric cancer cells by using network pharmacology and cytology experiments. In this paper, UPLC-MS/MS was used to identify the main chemical components in the extracts of D. officinale, and the an ADME model was used to screen the potential active components. Network pharmacology methods such as target prediction, pathway identification, and network construction were used to determine the mechanism through which the D. officinale extract inhibited gastric cancer cell proliferation. MTT assays, fluorescence confocal microscopy, clone formation, and flow cytometry were used to verify the inhibitory activity of the D. officinale extract on gastric cancer cell proliferation in vitro. The UPLC-MS/MS analysis identified 178 chemical components from the D. officinale extract. Network pharmacology analysis showed that 13 chemical components had the potential to inhibit the proliferation of gastric cancer cells, with the possible involvement of 119 targets and 20 potential signaling pathways. In vitro experiments confirmed that the D. officinale extract could significantly inhibit the proliferation of gastric cancer cells. Therefore, we believe that the D. officinale extract can inhibit the proliferation of gastric cancer cells through effects on multiple components, multiple targets, and multiple pathways.Entities:
Keywords: D. officinale; MTT; gastric cancer; network pharmacology; protein-protein interaction
Year: 2022 PMID: 35401206 PMCID: PMC8989831 DOI: 10.3389/fphar.2022.832134
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1Flowchart of the network pharmacological and experimental studies of the D. officinale extract in human gastric cancer cells.
FIGURE 2The molecular formulas of the 13 bioactive components identified from D. officinale extract.
Chemical formulae of the 13 bioactive components identified from D. officinale extract.
| No | Compound | Chemical formula | m/z |
|---|---|---|---|
| 1 | 3,4-Dihydroxybenzoic acid | C7H6O4 | 153.0218 |
| 2 | (±)-Naringenin | C15H12O5 | 135.0296 |
| 3 | 5-Hydroxytryptophan | C11H12N2O3 | 221.0851 |
| 4 | Swainsonine | C8H15NO3 | 174.1103 |
| 5 | Caffeic acid | C9H8O4 | 179.0350 |
| 6 | Serotonin | C10H12N2O | 177.1004 |
| 7 | 13-Cis-Acitretin | C21H26O3 | 325.1838 |
| 8 | Vanillin | C8H8O3 | 151.0401 |
| 9 | Caffeine | C8H10N4O2 | 91.0394 |
| 10 | Demethylimipramine | C18H22N2 | 231.1661 |
| 11 | (-)-Epicatechin | C15H14O6 | 313.0723 |
| 12 | Triptophenolide | C20H24O3 | 311.1678 |
| 13 | Sanguinarine | C20H14NO4 + | 355.0848 |
Gastric cancer-related targets of D. officinale extract.
| Number | Protein name | Gene name |
|---|---|---|
| 01 | Brain-derived neurotrophic factor | BDNF |
| 02 | Cyclin-dependent kinase inhibitor 1 | CDKN1A |
| 03 | Alpha-enolase | ENO1 |
| 04 | Interleukin-1 beta | IL1B |
| 05 | Interleukin-6 | IL6 |
| 06 | Prostaglandin G/H synthase 2 | PTGS2 |
| 07 | Superoxide dismutase [Mn] | SOD2 |
| 08 | Tumor necrosis factor | TNF |
| 09 | Alpha-fetoprotein | AFP |
| 10 | Aryl hydrocarbon receptor | AHR |
| 11 | Aldo-keto reductase family 1 member C3 | AKR1C3 |
| 12 | Albumin | ALB |
| 13 | Bcl-2-like protein 1 | BCL2L1 |
| 14 | G1/S-specific cyclin-D1 | CCND1 |
| 15 | Interleukin-8 | CXCL8 |
| 16 | Epidermal growth factor receptor | EGFR |
| 17 | Heme oxygenase 1 | HMOX1 |
| 18 | Mitogen-activated protein kinase 1 | MAPK1 |
| 19 | Mitogen-activated protein kinase 3 | MAPK3 |
| 20 | Mitogen-activated protein kinase 8 | MAPK8 |
| 21 | Peroxisome proliferator-activated receptor gamma | PPARG |
| 22 | Protein kinase C beta type | PRKCB |
| 23 | Plasminogen activator inhibitor 1 | SERPINE1 |
| 24 | Zinc finger protein SNAI1 | SNAI1 |
| 25 | Signal transducer and activator of transcription 3 | STAT3 |
| 26 | Cellular tumor antigen p53 | TP53 |
| 27 | Caspase-8 | CASP8 |
| 28 | Polyunsaturated fatty acid 5-lipoxygenase | ALOX5 |
| 29 | V-type proton ATPase subunit d 2 | ATP6V0D2 |
| 30 | Growth arrest and DNA damage-inducible protein GADD45 alpha | GADD45A |
| 31 | Glutathione S-transferase P | GSTP1 |
| 32 | Nitric oxide synthase | NOS3 |
| 33 | 5′-Nucleotidase | NT5E |
| 34 | Peroxiredoxin-5 | PRDX5 |
| 35 | 5-Hydroxytryptamine receptor 1A | HTR1A |
| 36 | Transcription factor AP-1 | JUN |
| 37 | 40S ribosomal protein S6 | RPS6 |
| 38 | Carbonic anhydrase 1 | CA1 |
| 39 | Carbonic anhydrase 2 | CA2 |
| 40 | Cytochrome P450 2A6 | CYP2A6 |
| 41 | DNA (cytosine-5)-methyltransferase 3B | DNMT3B |
| 42 | Fibroblast growth factor receptor 2 | FGFR2 |
| 43 | Metallothionein-2 | MT2A |
| 44 | Angiotensin-converting enzyme | ACE |
| 45 | Type-2 angiotensin II receptor | AGTR2 |
| 46 | DNA-(apurinic or apyrimidinic site) endonuclease | APEX1 |
| 47 | Apolipoprotein A-I | APOA1 |
| 48 | Serine-protein kinase ATM | ATM |
| 49 | BH3-interacting domain death agonist | BID |
| 50 | BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 | BNIP3 |
| 51 | Caveolin-1 | CAV1 |
| 52 | Cadherin-1 | CDH1 |
| 53 | Cyclin-dependent kinase 4 | CDK4 |
| 54 | Serine/threonine-protein kinase Chk2 | CHEK2 |
| 55 | Procathepsin L | CTSL |
| 56 | DNA (cytosine-5)-methyltransferase 1 | DNMT1 |
| 57 | Extracellular matrix protein 1 | ECM1 |
| 58 | Elongation factor 1-alpha 1 | EEF1A1 |
| 59 | Tyrosine-protein kinase Fyn | FYN |
| 60 | Gastrin | GAST |
| 61 | GTPase HRas | HRAS |
| 62 | Heat shock protein beta-1 | HSPB1 |
| 63 | Matrilysin | MMP7 |
| 64 | Adenine DNA glycosylase | MUTYH |
| 65 | Myc proto-oncogene protein | MYC |
| 66 | Prohibitin | PHB |
| 67 | 5′-AMP-activated protein kinase catalytic subunit alpha-1 | PRKAA1 |
| 68 | Major prion protein | PRNP |
| 69 | Regulator of G-protein signaling 2 | RGS2 |
| 70 | 60S ribosomal protein L13 | RPL13 |
| 71 | 40S ribosomal protein S19 | RPS19 |
| 72 | 40S ribosomal protein S26 | RPS26 |
| 73 | Plasminogen activator inhibitor 1 RNA-binding protein | SERBP1 |
| 74 | Alpha-1-antitrypsin | SERPINA1 |
| 75 | Sterol regulatory element-binding protein 2 | SREBF2 |
| 76 | Thymidylate synthase | TYMS |
| 77 | UL16-binding protein 2 | ULBP2 |
| 78 | Caspase-10 | CASP10 |
| 79 | Protein canopy homolog 2 | CNPY2 |
| 80 | Enoyl-CoA hydratase | ECHS1 |
| 81 | 60 kDa heat shock protein | HSPD1 |
| 82 | Interleukin-32 | IL32 |
| 83 | Insulin receptor substrate 2 | IRS2 |
| 84 | Nucleophosmin | NPM1 |
| 85 | Pyruvate dehydrogenase E1 component subunit alpha | PDHA1 |
| 86 | Urokinase-type plasminogen activator | PLAU |
| 87 | Peptidyl-prolyl cis-trans isomerase A | PPIA |
| 88 | Retinoic acid receptor beta | RARB |
| 89 | 60S ribosomal protein L18 | RPL18 |
| 90 | 40S ribosomal protein S15 | RPS15 |
| 91 | Protransforming growth factor alpha | TGFA |
| 92 | UBX domain-containing protein 1 | UBXN1 |
| 93 | Zinc finger protein 593 | ZNF593 |
| 94 | Beta-2 adrenergic receptor | ADRB2 |
FIGURE 3Component-target network of D. officinale extract and gastric cancer. The blue nodes represent candidate active components, and the red nodes represent potential protein targets. The edges represent the interactions between them, and the node sizes are proportional to the node degrees.
FIGURE 4Protein–protein interaction (PPI) network of D. officinale extract-related targets in gastric cancer.
FIGURE 5The degree value of the target protein (20%).
FIGURE 6List of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment results in relation to the potential targets of D. officinale extract. (A) The first 21 GO terms were identified based on p < .01. (B) The top 10 pathways were identified based on p < .01.
FIGURE 7Target-pathway network of the D. officinale extract. The red nodes represent the pathways, and the green nodes represent the targets. The size of the nodes is proportional to the degree of the node.
FIGURE 8Component–target–pathway network of the D. officinale extract. The green nodes represent the component, and the red nodes represent the targets and the blue nodes represent the pathways.
FIGURE 9D. officinale extract exhibited anti-cancer effects in SGC-7901, MGC-803, and MKN-45 cells. (A) The cell viability was assessed by MTT assay after D. officinale extract administration for 24 h. The cells were incubated with 0–2 mg/ml of D. officinale extract. n = 3. (B) Colony formation in the presence of D. officinale extract. n = 3. (C) Confocal laser analysis of GC cells treated with D. officinale extract. n = 3. (D) Apoptosis analysis of D. officinale extract-treated GC. n = 3. (E) Fluorescence quantitative detection of Caspase-3, Caspase-7, Caspase-9, Bax, and Bcl-2 after treating GC cells with .5 mg/ml D. officinale extract for 4 h *p < .05, **p < .01 vs. con.